Critical limb ischaemia as a main cause of death in patients with end-stage renal disease: a single-centre study
|
|
- Osborn Riley
- 5 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (2004) 19: doi: /ndt/gfh404 Advance Access publication 20 July 2004 Original Article Critical limb ischaemia as a main cause of death in patients with end-stage renal disease: a single-centre study Michael Koch 1, Rudolf Trapp 1, Wolfgang Kulas 1 and Bernd Grabensee 2 1 Centre of Nephrology Mettmann and 2 Department of Nephrology and Rheumatology, Heinrich Heine University, Du sseldorf, Germany Abstract Background. Patients with end-stage renal disease (ESRD) have a high overall mortality rate, particularly due to cardiovascular morbidity. In an era of decline in cardiovascular diseases and early cardiovascular intervention, non-cardiac diseases seem to have a larger impact on overall mortality. Methods. From 1997 to 2003, all incident haemodialysis patients in a single centre were enrolled in this prospective study. Those with clinical signs of vascular disease were examined by coronary or peripheral angiographies. Physicians took the patients medical histories, examined them and followed them up until the end of the study or death. Causes of death were defined by the physicians. Results. In all, 322 patients were enrolled in the study, 38% of whom were diabetic. At the start of dialysis treatment, 38% had coronary artery disease (CAD), defined as >50% stenosis of at least one coronary artery or as definite myocardial infarction, and 14% had critical ischaemia of at least one limb (CLI). In all patients with foot lesions, CLI was defined angiographically, as evidenced by stenosis or rarefication of distal vessels in the legs. Patients who died (n ¼ 121) [due to cardiac causes (n ¼ 25), complications of CLI (n ¼ 22), stroke (n ¼ 10), cachexia following a long-standing, non-malignant disease (n ¼ 6), malignancy (n ¼ 24), infection not related to CLI (n ¼ 18) and other causes (n ¼ 16)] were older (71±10 vs 65±13 years), more often male [74/121 (61%)] and often diabetic [56/121 (46%)]. CAD was documented in 82/121 (68%). Five-year survivals in patients with no risk and diabetes without CAD or CLI, CAD and CLI were 74%, 73%, 50% and 10%, respectively. Age, CLI and smoking habits independently increased the risk of death (hazard ratios: 1.052, and 2.292, respectively). Correspondence and offprint requests to: Michael Koch, MD, Gartenstrasse 8, Mettmann, Germany. koch@dialyse-mettmann.de Conclusions. These results indicate that CLI with associated complications is not only an indicator of high mortality in patients with ESRD, but is also one of the main causes of death. Keywords: causes of death; coronary artery disease; critical limb ischaemia; end-stage renal disease; mortality; peripheral arterial disease Introduction Haemodialysis patients have a high overall mortality rate. Depending on age, mortality rises from 518 to 924/1000 patient-years [1]. These death rates are comparable with those of colon cancer [2]. High cardiovascular morbidity is reported to be the main cause of death in >50% of these patients [1], though peripheral arterial disease (PAD) and its major complication, critical limb ischaemia (CLI), play minor roles [3]. PAD is common in patients with end-stage renal disease (ESRD), with a frequency of 24 77% [4 7]. The relative risk of death in patients with ESRD and PAD is 1.58 in comparison with ESRD patients with heart disease (1.59) [8]. One would expect that risk stratification, aggressive treatment of risk factors and the new technologies of dialysis facilities would lower the cardiovascular and overall mortalities, as reported in several studies [9,10]. Concomitantly, the incidence of cardiovascular disease seems to have decreased over recent years [11]. Nevertheless, overall mortality in ESRD dialysis patients remains high. Among reasons for this is the fact that the characteristics of dialysis populations have changed during recent years. The greatest contributors to the increase in the number of patients with ESRD have been older age and diabetes [1]. These last two characteristics are also the major risk factors of vascular morbidity and mortality in ESRD [12 14]. Data on the accuracy of the indicated causes of death in patients with ESRD are limited. The purpose of our Nephrol Dial Transplant Vol. 19 No. 10 ß ERA EDTA 2004; all rights reserved
2 2548 M. Koch et al. investigation was to determine prospectively and in a standardized way the causes of death in patients with ESRD and also whether or not clinical signs at the beginning of dialysis treatment might predict death. We are convinced that a more accurate determination of causes of death is of importance in the development of mortality-lowering interventions. Subjects and methods From 1997 to 2003, all eligible and incident haemodialysis patients in a single centre were enrolled in the study, but patients with acute renal failure were excluded. All patients were treated according to a high-quality standard protocol, which included regular quality controls along with antihypertensive therapy to lower systolic blood pressure to <140 mmhg, lipid-lowering therapy to lower low-density lipoprotein cholesterol to <130 mg/dl, optimized blood sugar control to reach HbA1c <7% and supplementation with erythropoietin and Fe. If there were no contraindications, patients received a platelet aggregation inhibitor. Concerning the dialysis, bicarbonate-buffered dialysate was used and potassium was measured for every dialysis session and haemoglobin once a week. The patients were dialysed for a total of 6 18 h/week, depending on residual renal function, and they were examined routinely twice a year. During the observation period, the patients were seen by the same medical doctors, who took their medical histories, examined the patients and followed the patients through the observation period or until their deaths. All patients were seen three times a week. The patients with angina pectoris had a coronary angiography and coronary artery disease (CAD) was diagnosed when a stenosis of >50% was observed in at least one coronary artery. If angiography was not performed, CAD was diagnosed in a patient with a history of myocardial infarction and concomitant changes in the electrocardiogram. Peripheral angiography was performed in all symptomatic patients with foot lesions, such as ulceration or gangrene. CLI was diagnosed if angiography showed one or more of stenosis, slow flow phenomenon, rarefication of one or more of the peripheral arteries and if patients had ulceration or gangrene. Causes of death were defined as follows: Cardiovascular death, if a patient was hospitalized due to myocardial Table 1. Characteristics of 322 incident ESRD patients at baseline infarction with elevated levels of creatine kinase and concomitant changes in the electrocardiogram; sudden death, if a patient died unexpectedly at home; and cardiac death, due to inoperable aortic stenosis, congestive heart failure, etc. A death due to cardiac causes was defined even in a patient who had a malignancy, if a myocardial infarction was the immediate cause of death. Deaths due to CLI were defined if patients died due to sepsis or if they were malnourished after prolonged hospitalizations and were on chronic analgesia and antibiotic therapy, but if one of these patients died due to a myocardial infarction, the death was listed as a cardiovascular death. Statistical analysis Statistical analyses were performed using the SAS system for Windows Õ, version 8.2 (SAS Institute, Cary, NC, USA). CLI and CAD definition at baseline included those patients who developed CLI or CAD 6 months after starting dialysis. Survival time was calculated from the start of dialysis treatment. We censored all cases who did not survive the first 6 months on dialysis and those who received a renal graft during the observation period. Survival and mortality were estimated by life tables and survival distribution function was assessed according to the Kaplan Meier method. To compare patients with different risks at baseline, we formed four risk groups: patients with CLI, with CAD or with diabetes and, in cases where no former risks were present, patients with no risks. This implies that, for example, patients with CLI could have had diabetes or CAD concomitantly or patients with CAD could have had diabetes. The Cox proportional hazards model was used to prove independency of covariates such as age, sex, diabetes, smoking, CLI and CAD at baseline. Results We examined 322 patients with a mean age of 67 years (range: years) at the start of dialysis treatment, of whom 57% were males and 38% were diabetics. At baseline (6 months after initiating dialysis), 38% of the patients were found to have CAD. Patients with CAD were older, were more likely to be men All patients Diabetes No diabetes CAD No CAD CLI No CLI Patients (n) Age (years) 67 ± 12 69±9 66±14 71±10 65±13 a 67±10 67±13 % Diabetes b a % Male b b % Smoker c % CLI c 25 7 a % CAD b a % Low aspirin d % Statin c b Weight (kg) 74±16 75±18 73±16 73±14 74±16 79±20 73±16 d Systolic RR (mmhg) 138±17 138±19 138±16 138±17 139±17 134±16 139±18 Diastolic RR (mmhg) 77±7 76±7 78±7 76±7 78±7 75±7 77±8 Chi-square and Student s t-test: a P<0.0001; b P<0.01; c P<0.001; d P<0.05. Systolic and diastolic RR is self declared.
3 Critical limb ischaemia in ESRD 2549 Table 2. Prevalence (at baseline) and incidence (at follow-up 6 12 and >12 months later) of cardiac and peripheral events in 322 incident ESRD patients Total Time 0 prevalence (þ6 months) Time 1 incidence (6 12 months) Time 2 incidence (>12 months) CAD MI Angioplasty CABG CLI Gangrene Angioplasty Bypass Minor amputation Major amputation MI, myocardial infarction. CABG, coronary artery bypass graft. Table 3. Causes of death in incident ESRD patients with CLI or CAD at baseline and, in those who developed CLI or CAD, during follow-up Total (n ¼ 322) CLI prevalent (n ¼ 34) and to have diabetes mellitus, were often smokers, suffered more often from CLI and were more often on aspirin and statins than patients without CAD (Table 1). On the other hand, 14% of the patients had CLI at baseline. Patients with CLI were more frequently men and diabetic, had higher body weights and were more likely to be on statins than patients without CLI (Table 1). The prevalence (at baseline) and incidence (>12 months) of vascular events are listed in Table 2. Most of the patients started dialysis treatment with a tremendous burden of vascular damage. During follow-up, only a small proportion of patients developed new vascular events (probability of denovo CLI see fig. 2), 121 patients died and 12 patients received kidney grafts. Those who did not survive 6 months (n ¼ 41) were censored. No patient was lost to follow-up. The causes of death and their incidences are listed in Table 3. The most important cause of death was cardiovascular (21%) deaths that followed myocardial infarction (n ¼ 6), sudden death (n ¼ 14) and other cardiac causes (n ¼ 5). Death following CLI was observed in 22 out of 121 patients (18%) (Table 3). All of those who died due to CLI had non-healing foot lesions; C-reactive CLI incident (n ¼ 25) CAD prevalent (n ¼ 122) CAD incident (n ¼ 46) Number of deaths 121 (38%) 22 (65%) 15 (60%) 62 (50%) 20 (43%) Cardiovascular 25 (21%) (27%) 5 (25%) Myocardial infarction Sudden death Other cardiac causes CLI 22 (18%) 13 (59%) 9 (60%) 12 (19%) 7 (35%) Cerebral vascular 10 (8%) 1 (6%) 0 5 (8%) 2 (10%) Long-standing disease 6 (5%) 1 (6%) 0 4 (10%) 1 (5%) Malignancy 24 (20%) 2 (9%) 1 (7%) 8 (13%) 2 (10%) Infection/sepsis a 18 (13%) 1 (6%) 2 (13%) 7 (6%) 2 (5%) Other causes 16 (12%) 0 1 (7%) 9 (15%) 1 (5%) a Not related to CLI. Table 4. Characteristics of 22 ESRD patients who died due to CLI Long-standing therapy with antibiotics (>30 days) n ¼ 18 Hospitalization per patient (days/last 6 months) 39±18 Chronic use of analgesic drugs n ¼ 22 Weight loss (>5 kg/last 6 months) n ¼ 15 C-reactive protein before death (mg/l) 105±34 Haemoglobin before death (g/%) 10±1.2 Angioplasty n ¼ 14 Surgical revascularization n ¼ 4 Major amputation n ¼ 13 Minor amputation n ¼ 4 Time from amputation until death in 30±42 15 patients (days) Multiresistant Staphylococcus n ¼ 6 protein was high in a majority of these patients. These 22 patients had prolonged hospitalizations, were bedridden and on chronic antibiotic therapy, colonized by multiresistant bacteria, needed daily analgesia, suffered from significant weight loss and had multiple surgical interventions with local wound debridement, necrectomy, angioplasty, bypass grafting and minor and major amputations (Table 4). Of patients with CLI and major amputations, 10 of 26
4 2550 M. Koch et al Survival Distribution Function Time STRATA: No risk Diabetes CAD CLI all pts no risk Diabetes CAD CLI Fig. 1. Survival in 322 ESRD patients with no risk, diabetes, CAD and CLI during 5 years of observation. Table 5. Stepwise proportional hazards model with age, sex diabetes, smoker, CAD and CLI as explanatory variables Variable Number 2 P-value Hazard ratio SE CLI < Age < Smoker survived. No patient was withdrawn from dialysis. Patients who died tended to be older (71±10 vs 65±13 years), male [74/121 (61%)] and diabetic [56/121 (46%)]. Most of the patients who died were known to have CAD (68%), but cardiovascular death was established in only 21%. Patients with CLI carry the highest mortality risk. According to life-table analyses, the 5 year survival rate in patients with no risk was 74%, in diabetics without CAD or CLI 73%, in CAD 50% and in CLI 10% (Figure 1). The application of the Cox proportional hazards model included significant variables, such as age, diabetes, sex, smoking habits, CAD and CLI, at baseline and it yielded an independent increase in the risk of death for each of CLI, age and smoking (hazard ratios: 4.921, and 2.292, respectively; Table 5). Discussion This study has two important findings. First, if ESRD patients start dialysis with foot lesions, such as ulceration or gangrene resulting from PAD, their risk of dying is elevated, independently of diabetes or CAD. Second, the complications of CLI are among the main causes of death in ESRD patients. All patients who died of these causes were hospitalized and most of them needed morphine for pain. The majority of patients were on prolonged antibiotic therapy, if systemic inflammation was present. Nearly all patients were hospitalized for long periods, during which they underwent angioplasty, surgical reconstruction and, as a last option, amputation. Predominantly, these patients were old, diabetic and had stable CAD. Their deaths did not follow cardiovascular events, such as myocardial infarction, etc.; these patients died due to infection, sepsis or multiorgan failure after being bedridden. Our results are in accordance with the results of Jaar et al. [15], who found that older age and preexisting PAD were independent risk factors for sepsis and death in ESRD patients. The long-term outcome in patients with PAD and ESRD is worse. In patients with infra-inguinal bypass grafting, 2 year survival was only 42% [16]. In view of this markedly increased mortality, reconstructive intervention for these patients must be considered highly palliative. In multivariate analysis, those patients in our study with CLI had the highest mortality risk. Age at the start of dialysis treatment, smoking habits and CLI independently increased the risk of death according to the Cox proportional hazards model. Surprisingly, CAD did not meet the significance level of P ¼ 0.05 for entry
5 Critical limb ischaemia in ESRD 2551 Fig. 2. Probability for de novo CLI in 322 ESRD patients, depending on time on dialysis. into the model. An explanation of this phenomenon could be that CAD was frequent, despite strict diagnostic criteria, but deaths due to CAD were relatively few. On the other hand, CLI was less frequent than CAD, but death due to CLI was relatively high. The death rate due to CLI in our study is relatively high compared with corresponding numbers in the USRDS [3] and the HEMO Study [5]. The difference may be due to differences in population sampling. For instance, the HEMO Study excluded patients with chronic inflammation (serum albumin <2.6 g/l) and patients older than 80 years. It is possible that comorbid conditions, such as PAD or CLI, are under-reported [17]. A recently published study [18] has demonstrated the importance of PAD concerning mortality rates in ESRD patients. The 5 year survival rates of coronary artery bypass-grafted patients without renal failure, with renal failure and with renal failure and PAD or diabetes were 83.5%, 78.5% and 42%, respectively. In our study, patients with CLI had a 5 year survival of only 10%, independent of concomitant diabetes or CAD. The above-mentioned study does not refer at all to the possible causes of deaths in its cohort. One could speculate that the high proportion of deaths due to CLI is a single-centre bias. In a large study in Britain of 1718 patients undergoing angioplasty due to PAD, 16/69 (23%) patients with chronic renal failure died within 30 days after vascular reconstruction; the highest mortality was found in patients undergoing emergency surgery [19]. The median survival of ESRD patients undergoing arterial reconstructive surgery was 1.72 years compared with 5.17 years in a general population [20]. Our results indicate that an early amputation of a critical ischaemic limb would probably prevent death, but our experience is that only a small proportion of patients agree to this radical procedure. Treatment options for these patients are few and further studies should focus on the question of whether or not patients have a better chance of surviving with an amputation and, if so, whether or not there is a critical time to perform the amputation. Conflict of interest statement. None declared. References 1. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ. Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol 2000; 152: VI. Causes of death in ESRD. Am J Kidney Dis 1999; 34: S87 S94 4. O Hare AM, Hsu CY, Bacchetti P, Johansen KL. Peripheral vascular disease risk factors among patients undergoing hemodialysis. J Am Soc Nephrol 2002; 13: Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: Leskinen Y, Salenius JP, Lehtimaki T, Huhtala H, Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis 2002; 40: Schleiffer T, Holken H, Brass H. Morbidity in 565 type 2 diabetic patients according to stage of nephropathy. J Diabetes Complic 1998; 12:
6 2552 M. Koch et al. 8. Johnson JG, Gore SM, Firth J. The effect of age, diabetes, and other comorbidity on the survival of patients on dialysis: a systematic quantitative overview of the literature. Nephrol Dial Transplant 1999; 14: Meier-Kriesche HU, Ojo AO, Port FK et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001; 12: Port FK, Orzol SM, Held PJ, Wolfe RA. Trends in treatment and survival for hemodialysis patients in the United States. Am J Kidney Dis 1998; 32: S34 S Foley RN, Herzog CA, Collins AJ. Declining incidence of cardiovascular disease in older end-stage renal disease patients in the United States, J Am Soc Nephrol 2002; 13: 432A 12. Berthoux F, Gellert R, Jones E et al. Epidemiology and demography of treated end-stage renal failure in the elderly: from the European Renal Association (ERA EDTA) Registry. Nephrol Dial Transplant 1998; 13 [Suppl 7]: Koch M, Thomas B, Tschope W, Ritz E. Survival and predictors of death in dialysed diabetic patients. Diabetologia 1993; 36: Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997; 12: Jaar BG, Hermann JA, Furth SL, Briggs W, Powe NR. Septicemia in diabetic hemodialysis patients: comparison of incidence, risk factors, and mortality with nondiabetic hemodialysis patients. Am J Kidney Dis 2000; 35: Albers M, Romiti M, Braganca-Pereira CA, Fonseca RL, Silva- Junior M. A meta-analysis of infrainguinal arterial reconstruction in patients with end-stage renal disease. Eur J Vasc Endovasc Surg 2001; 22: Longenecker JC, Coresh J, Klag MJ et al. Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. J Am Soc Nephrol 2000; 11: Dacey LJ, Liu JY, Braxton JH et al. Long-term survival of dialysis patients after coronary bypass grafting. Ann Thorac Surg 2002; 74: Gerrard DJ, Ray SA, Barrio EA et al. Effect of chronic renal failure on mortality rate following arterial reconstruction. Br J Surg 2002; 89: Reddan DN, Marcus RJ, Owen W-FJ, Szczech LA, Landwehr DM. Long-term outcomes of revascularization for peripheral vascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38: Received for publication: Accepted in revised form:
Echocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationOUT OF DATE. Coronary artery, cerebrovascular and peripheral vascular disease
19..23 NEPHROLOGY 2010; 15, S19 S23 doi:10.1111/j.1440-1797.2010.01227.x Coronary artery, cerebrovascular and peripheral vascular disease Date written: December 2008 Final submission: March 2009nep_1227
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationPOOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS
POOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS CHARLES A. HERZOG, M.D., JENNIE Z. MA, PH.D., AND ALLAN J. COLLINS, M.D. ABSTRACT Background Cardiovascular
More informationLIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:
LIBERTY 360 Study LIBERTY is a prospective, observational, multi-center study to evaluate procedural and long-term clinical and economic outcomes of endovascular device interventions in patients with symptomatic
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationChapter 9: Cardiovascular Disease in Patients With ESRD
Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in adult ESRD patients, with atherosclerotic heart disease and congestive heart failure being the most common conditions
More informationAJNT. Original Article
. 2012 May;5(2):81-6 Original Article AJNT Reaching Target Hemoglobin Level and Having a Functioning Arteriovenous Fistula Significantly Improve One Year Survival in Twice Weekly Hemodialysis Sarra Elamin
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationRandomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationSPINACH Making Limb Salvage Salad from Spinach alone
SPINACH Making Limb Salvage Salad from Spinach alone Surgical reconstruction versus Peripheral Intervention in patients with critical limb ischemia prospective multicenter registry in Japan Nobuyoshi Azuma,
More informationCAD in Chronic Kidney Disease. Kuang-Te Wang
CAD in Chronic Kidney Disease Kuang-Te Wang InIntroduction What I am going to talk about: CKD and its clinical impact on CAD Diagnosis of CAD in CKD PCI / Revasc Outcomes in CKD CKD PCI CAD Ohtake T,
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationAngiosome concept myth or truth? Does it make a real difference in real world cases?
Angiosome concept myth or truth? Does it make a real difference in real world cases? Osamu Iida, MD, FACC Kansai Rosai Hospital Amagasaki, Hyogo, Japan Disclosure Speaker name:... I have the following
More informationChapter 8: Cardiovascular Disease in Patients with ESRD
Chapter 8: Cardiovascular Disease in Patients with ESRD Cardiovascular disease (CVD) is common in adult end-stage renal disease (ESRD) patients, with coronary artery disease (CAD) and heart failure (HF)
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationImproved survival of type 2 diabetic patients on renal replacement therapy in Finland
Nephrol Dial Transplant (2010) 25: 892 896 doi: 10.1093/ndt/gfp555 Advance Access publication 21 October 2009 Improved survival of type 2 diabetic patients on renal replacement therapy in Finland Marjo
More informationRenal Insufficiency and Use of Revascularization among a National Cohort of Men with Advanced Lower Extremity Peripheral Arterial Disease
Renal Insufficiency and Use of Revascularization among a National Cohort of Men with Advanced Lower Extremity Peripheral Arterial Disease Ann M. O Hare,* Daniel Bertenthal, Anton N. Sidawy,** Michael G.
More informationCJASN epress. Published on January 4, 2006 as doi: /CJN
CJASN epress. Published on January 4, 2006 as doi: 10.2215/CJN.01070905 Renal Insufficiency and Use of Revascularization among a National Cohort of Men with Advanced Lower Extremity Peripheral Arterial
More informationPractical Point in Holistic Diabetic Foot Care 3 March 2016
Diabetic Foot Ulcer : Vascular Management Practical Point in Holistic Diabetic Foot Care 3 March 2016 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More information3-year results of the OLIVE registry:
3-year results of the OLIVE registry: A prospective multicenter study in patients with critical limb ischemia Osamu Iida, MD Kansai Rosai Hospital Cardiovascular Center Amagasaki, Hyogo, Japan Disclosure
More informationChronic renal disease in the elderly: are all pigs to be considered equal?
Chronic renal disease in the elderly: are all pigs to be considered equal? W. Van Biesen, Ghent University Hospital Elwood et al, cjasn, 2013 Elderly and CKD: a thematic synthesis Overview CKD in the
More informationEasy. Not so Easy. Risk Assessment in the CLI Patient: Who is Likely to Benefit from Revascularization and Who is Not? 4/28/2012
Risk Assessment in the CLI Patient: Who is Likely to Benefit from Revascularization and Who is Not? Easy 89 yo Non-ambulatory Multiple failed interventions Forefoot and heel gangrene Andres Schanzer, MD
More informationCurrent Vascular and Endovascular Management in Diabetic Vasculopathy
Current Vascular and Endovascular Management in Diabetic Vasculopathy Yang-Jin Park Associate professor Vascular Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine Peripheral artery
More informationOlive registry: 3-years outcome of BTK intervention in Japan. Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan
Olive registry: 3-years outcome of BTK intervention in Japan Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan What is the optimal treatment for the patient with critical limb ischemia (CLI)?
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More information9/7/2018. Disclosures. CV and Limb Events in PAD. Challenges to Revascularization. Challenges. Answering the Challenge
Disclosures State-of-the-Art Endovascular Lower Extremity Revascularization Promotional Speaker Jansen Pharmaceutical Promotional Speaker Amgen Pharmaceutical C. Michael Brown, MD, FACC al Cardiology Associate
More informationMaximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia
Maximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia Traci A. Kimball, MD Department of Surgery Grand Rounds Septemember 13, 2010 Overview Defining Critical Limb Ischemia Epidemiology
More informationDisclosures. Talking Points. An initial strategy of open bypass is better for some CLI patients, and we can define who they are
An initial strategy of open bypass is better for some CLI patients, and we can define who they are Fadi Saab, MD, FASE, FACC, FSCAI Metro Heart & Vascular Metro Health Hospital, Wyoming, MI Assistant Clinical
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationPeripheral Arterial Occlusive Disease- The Challenge in patients with diabetes
Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes Ashok Handa Reader in Surgery and Consultant Surgeon Nuffield Department of Surgery University of Oxford Introduction Vascular
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationIntroduction. Risk factors of PVD 5/8/2017
PATHOPHYSIOLOGY AND CLINICAL FEATURES OF PERIPHERAL VASCULAR DISEASE Dr. Muhamad Zabidi Ahmad Radiologist and Section Chief, Radiology, Oncology and Nuclear Medicine Section, Advanced Medical and Dental
More informationOriginal Article. Charles A. Herzog 1,2, Jeremy W. Strief 1, Allan J. Collins 2,3 and David T. Gilbertson 3. Introduction
Nephrol Dial Transplant (2008) 23: 2629 2633 doi: 10.1093/ndt/gfn038 Advance Access publication 25 February 2008 Original Article Cause-specific mortality of dialysis patients after coronary revascularization:
More informationIn the general population, patients with peripheral arterial
Impact of Renal Insufficiency on Mortality in Advanced Lower Extremity Peripheral Arterial Disease Ann M. O Hare,* Daniel Bertenthal, Michael G. Shlipak, Saunak Sen, Mary-Margaret Chren *Divisions of Nephrology
More informationSurgery for Acquired Cardiovascular Disease
Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery Rajendra H. Mehta, MD, MS, a Gail E. Hafley, MS,
More informationDR as a Biomarker for Systemic Vascular Complications
DR as a Biomarker for Systemic Vascular Complications Lihteh Wu MD Asociados de Mácula, Vítreo y Retina de Costa Rica San José, Costa Rica LW65@cornell.edu Disclosures Dr Wu has received lecture fees from
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in ESRD patients, with atherosclerotic heart disease and congestive heart
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationHospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension
(2003) 17, 665 670 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Hospital and 1-year outcome after acute myocardial infarction in patients with
More informationCRITICAL LIMB ISCHEMIA UNITED STATES EPIDEMIOLOGY TABLE OF CONTENTS
CRITICAL LIMB ISCHEMIA UNITED STATES EPIDEMIOLOGY TABLE OF CONTENTS CRITICAL LIMB ISCHEMIA... 1 CONCLUSION... 9 U.S. CRITICAL LIMB ISCHEMIA PREVALENCE... 9 MARKET OPPORTUNITY ENDOVASCULAR... 9 MARKET OPPORTUNITY
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationDisclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb
Saphenous Vein Grafts with Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes from the Project of Ex-vivo Vein Graft
More informationTreatment Strategies For Patients with Peripheral Artery Disease
Treatment Strategies For Patients with Peripheral Artery Disease Presented by Schuyler Jones, MD Duke University Medical Center & Duke Clinical Research Institute AHRQ Comparative Effectiveness Review
More informationACC NY Cardiovascular Symposium
ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationBeta-blockers for coronary heart disease in chronic kidney disease
Nephrol Dial Transplant (2008) 23: 2274 2279 doi: 10.1093/ndt/gfm950 Advance Access publication 10 January 2008 Original Article Beta-blockers for coronary heart disease in chronic kidney disease Michel
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationNational Vascular Registry
National Vascular Registry Bypass Patient Details Patient Consent* 2 Not Required If patient not consented: Date consent recorded / / (DD/MM/YYYY) Do not record NHS number, NHS number* name(s) or postcode.
More informationNow That You Have the Tools
blockosu@gmail.com Now That You Have the Tools Alan Jay Block, DPM, MS, FASPS, FACFAS Assistant Professor Dept Of Orthopeadics The Ohio State University Medical Board Kent State University Editor-in -Chief
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationPractical Point in Diabetic Foot Care 3-4 July 2017
Diabetic Foot Ulcer : Role of Vascular Surgeon Practical Point in Diabetic Foot Care 3-4 July 2017 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai University
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationImpact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,
More informationAngina or intermittent claudication: which is worse?
Angina or intermittent claudication: which is worse? A comparison of self-assessed general health, mental health, quality of life and mortality in 7,403 participants in the 2003 Scottish Health Survey.
More informationHaemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health
Haemodiafiltration - the case against Prof Peter G Kerr Professor/Director of Nephrology Monash Health Know your opposition.. Haemodiafiltration NB: pre or post-dilution What is HDF how is it different
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationLong-term outcomes in nondiabetic chronic kidney disease
original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Blood urea sampling methods GUIDELINES
Date written: November 2004 Final submission: July 2005 Blood urea sampling methods GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions are
More information4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
More informationSupplemental Table 1. Standardized Serum Creatinine Measurements. Supplemental Table 3. Sensitivity Analyses with Additional Mortality Outcomes.
SUPPLEMENTAL MATERIAL Supplemental Table 1. Standardized Serum Creatinine Measurements Supplemental Table 2. List of ICD 9 and ICD 10 Billing Codes Supplemental Table 3. Sensitivity Analyses with Additional
More informationTRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA
& TRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA 2002-2008 Halima Resić* 1, Enisa Mešić 2 1 Clinic for Hemodialysis, University of Sarajevo Clinics Centre, Bolnička 25, 71000 Sarajevo, Bosnia
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationLarry Diaz, MD, FSCAI Mehdi H. Shishehbor, DO, FSCAI
PAD Diagnosis Larry Diaz, MD, FSCAI Metro Health / University of Michigan Health, Wyoming, MI Mehdi H. Shishehbor, DO, FSCAI University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH PAD:
More informationSilent cerebral infarction predicts vascular events in hemodialysis patients
Kidney International, Vol. 67 (2005), pp. 2434 2439 Silent cerebral infarction predicts vascular events in hemodialysis patients TOSHIHIDE NAGANUMA,JUNJI UCHIDA,KENJI TSUCHIDA, YOSHIAKI TAKEMOTO, SHINJI
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationOutcome of elderly patients with severe but asymptomatic aortic stenosis
Outcome of elderly patients with severe but asymptomatic aortic stenosis Robert Zilberszac, Harald Gabriel, Gerald Maurer, Raphael Rosenhek Department of Cardiology Medical University of Vienna ESC Congress
More informationHow is the dialysis patient different?
How is the dialysis patient different? Mihály Tapolyai, MD, FASN, FACP Fresenius Medical Care SOTE, Budapest; Hungary Minneapolis VAMC, Minneapolis, MN; USA How is the dialysis patient different? Dialysis
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationEvolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC)
Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC) W. Schuyler Jones, MD FACC Director, Adult Cardiac Catheterization Laboratory
More informationImprovements in immunosuppressive medication, organ
JASN Express. Published on April 27, 2005 as doi: 10.1681/ASN.2004121092 Impact of Cadaveric Renal Transplantation on Survival in Patients Listed for Transplantation Gabriel C. Oniscu,* Helen Brown, John
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationIntercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2
Lipid Abnormalities Remain High among Treated Hypertensive Patients with Stable CHD: Results of the Dyslipidemia International Study (DYSIS) II Belgium Michel Guillaume 1, Eric Weber 2, Johan De Sutter
More informationNephrology Unit- CHU Liège- Ulg- Belgium
Are the complications of arteriovenous fistulas associated with an abnormal Ankle-Brachial Index in Hemodialysis? A 4y study P. Xhignesse, A. Saint-Remy, B. Dubois, JC. Philips, JM. Krzesinski Nephrology
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationJohn E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationThe Prognostic Importance of Comorbidity for Mortality in Patients With Stable Coronary Artery Disease
Journal of the American College of Cardiology Vol. 43, No. 4, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.10.031
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationClinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease
Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon
More informationEndovascular Should Be Considered First Line Therapy
Revascularization of Patients with Critical Limb Ischemia Endovascular Should Be Considered First Line Therapy Michael Conte David Dawson David L. Dawson, MD Revised Presentation Title A Selective Approach
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More information